Are we giving enough HCQ?🤔 Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48) #ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim

Is he the only one? Dr. Stone shared that he kept his notes from internship and residency! I kept an old tshirt from college, but this is a new level. #ACR22 @rheumnow https://t.co/Wj9c2Uizxt

Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX

FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY) Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY) IR MACE & mortality NSAID < Opioids Driven by VTE > Opioids vs NSAIDs HR=2.45 https://t.co/fl7cJNGrvu Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl

Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persisted in non-smokers, non-RA-ILD, incident RA @RheumNow #ACR22 Abstr#1647 #ACRbest https://t.co/c18k9OLDIm https://t.co/UTgYZAmfmk

Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (age < 18) @rheumnow https://t.co/dZ02kuOUeH

Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 . ILD first HR 8.4 @RheumNow #ACR22 Abstr#1959 #ACRbest https://t.co/mnbeBPuyC7 https://t.co/sLU2ZuTMw7

Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to all of ultrasound, MRI, and PET/CT. Nice summary slide @drceowen #ACR22 @RheumNow https://t.co/1LO3DvW7tm

14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Special pops recs for: Organ transplant - against romosozumab (CVD risk) Women of child bearing age (not planning) - BIS/TERI Children - Vit D/Ca unless Fx Very high doses: more aggressive @RheumNow https://t.co/xY7Yc3BANj

Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeostasis. Exciting for rheumatic disease beyond RA. @RheumNow #ACR22 #LateBreaking https://t.co/oOjvo5YmDB

Tam et al . Increased CV risk in early RA abrogated with treat to target approach. @RheumNow #ACR22 Abstr#1649 https://t.co/i2iHyPoKf0 https://t.co/u0R00oolyP